menu search

Immupharma plc partner makes final preparations for phase iii trial

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) said its US partner has sought final regulatory guidance from the Food & Drug Administration as it ‘actively pre...

June 27, 2022, 3:12 am

Rigel (rigl) waiha study fails to meet goals, stock tanks

Rigel (RIGL) phase III study evaluating fostamatinib in patients with warm autoimmune hemolytic anemia ...

June 9, 2022, 2:17 pm

Immunic, inc. to participate in scientific, industry and investor conferences in june

NEW YORK , June 8, 2022 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective ...

June 8, 2022, 6:30 am

Immunovant to report fourth quarter and full year 2022 financial results on june 8, 2022

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal liv...

June 6, 2022, 4:47 pm

Argenx to present at upcoming investor conferences

June 1 , 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suff...

June 1, 2022, 1:00 am

Brickell biotech to report first quarter 2022 financial results and provide a corporate update on may 12, 2022

BOULDER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmace...

May 5, 2022, 4:01 pm

Argenx to present at bofa securities 2022 healthcare conference

May 4 , 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffe...

May 4, 2022, 1:00 am

Alpine immune sciences announces participation in may investor conferences

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative...

May 3, 2022, 8:05 am

Argenx to report first quarter 2022 financial results and business update on may 5, 2022

April 28, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suf...

April 28, 2022, 1:00 am

Argenx (argx) up on positive autoimmune disorder study data

argenx (ARGX) plans to file a BLA for the SC formulation of efgartigimod, developed using Halozyme's ENHANZE technology, for treating myasthenia gravi...

March 23, 2022, 9:47 am

Argenx's subcutaneous efgartigimod at par with intravenous administration in neuromuscular disorder

Argenx SE (NASDAQ: ARGX) ) has announced topline data from the Phase 3 ADAPT-SC study evaluating subcutaneous (SC) efgartigimod for generalized mya...

March 22, 2022, 12:30 pm

Shattuck labs to present two posters at the 2022 american association for cancer research (aacr) annual meeting

AUSTIN, Texas and DURHAM, N.C., March 09, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology compa...

March 9, 2022, 8:21 am

Xencor to present preclinical data from xmab® cytokine programs at the american association for cancer research (aacr) annual meeting 2022

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytoki...

March 8, 2022, 4:31 pm

Vyne therapeutics' bet inhibitor shows encouraging preclinical action in skin disorder

VYNE Therapeutics Inc (NASDAQ: VYNE) has announced preclinical data in an ex vivo skin model of vitiligo, a chronic ...

March 7, 2022, 12:06 pm

Vyne therapeutics' bet inhibitor shows encouraging preclinical action in skin disorder

VYNE Therapeutics Inc (NASDAQ: VYNE) has announced preclinical data in an ex vivo skin model of vitiligo, a chronic ...

March 7, 2022, 12:06 pm

Vyne therapeutics' bet inhibitor shows encouraging preclinical action in skin disorder

VYNE Therapeutics Inc (NASDAQ: VYNE) has announced preclinical data in an ex vivo skin model of vitiligo, a chronic ...

March 7, 2022, 12:06 pm

Ventyx biosciences to participate in the barclays global healthcare conference

ENCINITAS, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx” or the “Company”), a clinical-stage bi...

March 7, 2022, 8:00 am

Ventyx biosciences to participate in the barclays global healthcare conference

ENCINITAS, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx” or the “Company”), a clinical-stage bi...

March 7, 2022, 8:00 am

Ventyx biosciences to participate in the barclays global healthcare conference

ENCINITAS, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx” or the “Company”), a clinical-stage bi...

March 7, 2022, 8:00 am

Annexon biosciences to present preclinical data supporting complement inhibitor programs for the treatment of guillain-barré syndrome and huntington's disease at aan 2022

BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developi...

March 3, 2022, 4:01 pm


Search within

Pages Search Results: